Agenus
Agenus is a Massachusetts immuno-oncology company developing botensilimab, an Fc-enhanced anti-CTLA-4 antibody, with its anti-PD-1 balstilimab, notably in microsatellite-stable colorectal cancer where checkpoint inhibitors have not worked.
Overview
Agenus, based in Lexington, Massachusetts and listed on Nasdaq, develops checkpoint antibodies and cancer vaccines. Its lead combination is botensilimab, a next-generation anti-CTLA-4 antibody with an engineered Fc region, given with balstilimab, an anti-PD-1 antibody, which has shown responses in microsatellite-stable colorectal cancer without liver metastases and other cold tumours; the company has sought accelerated approval and runs registrational trials. OnCo records it as a registry sponsor of phase 3 cancer trials.
Scorecard
All companies- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +11
Similar pages
not linked directly; found by shared links- CompanySTCube
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyTiumBio
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyShanghai Kechow Pharma
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyMabwell (Shanghai) Bioscience
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyOncolytics Biotech
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyVyriad
Shares Colorectal cancer and the tag ctgov-sponsor.